SEQUENCE LISTING

```
<110> University of Warwick
<120> Antibody Secretion
<130> P708122GB
<140> GB0226787.7
<141>
      2002-11-18
<160>
      69
<170> PatentIn version 3.2
<210>
<211>
      6
<212>
      PRT
<213> Artificial
<220>
<223> Modified targeting signal in the final antibody heavy chain
<220>
       MISC FEATURE
<221>
<222>
       (1)...(1)
<223> Asn, His or Leu
<220>
<221> MISC_FEATURE
<222>
       (2)..(2)
<223> Val or Tyr
<220>
<221> MISC FEATURE
<222>
       (3)..(3)
<223> Ser or Asn
<220>
<221>
       MISC_FEATURE
<222>
       (5)..(5)
<223> An aliphatic amino acid, especially Val or Leu
<220>
<221>
       misc feature
<222>
       (6)..(6)
<223>
       Xaa can be any naturally occurring amino acid
<400>
Xaa Xaa Xaa Val Ser Xaa
                5
<210>
       2
<211>
       6
<212>
       PRT
<213>
      Artificial
<220>
<223>
       Modified targeting signal in the final antibody heavy chain
<400>
       2
```

```
Asn Val Ser Val Ser Val
<210>
       3
<211>
       3
<212>
       PRT
<213> Artificial
<220>
<223>
       Modified targeting signal in the final antibody heavy chain
<220>
<221>
       MISC_FEATURE
<222>
       (1)..(1)
<223> m copies of, independently, any amino acid with the proviso that
       it is not selected from Ile, Leu or forms the consecutive
       sequence described in SEQ ID:4. m is an integer of at least 2.
       Preferably, m is between 4 and 20, especially 5 to 10.
<220>
<221>
       MISC_FEATURE
<222>
       (3)..(3)
       n copies of any amino acid, the presence of each amino acid is
<223>
       independent of the other(s). n is an integer of 0 to 5.
       Preferably n= 0 or 1, especially 1. This amino acid is most
       preferably Tyr or Ala, especially Ala. Preferably
<400> 3
Xaa Cys Xaa
<210>
<211>
       6
<212>
       PRT
<213> Artificial
<220>
<223> Definition of X at position 1 in SEQ ID: 3
<220>
<221>
       MISC FEATURE
<222>
       (1)...(1)
<223>
       Asn, His or Leu
<220>
<221> MISC FEATURE
<222>
       (2)...(2)
<223> Val or Tyr
<220>
 <221>
       MISC_FEATURE
 <222>
        (3)..(3)
<223>
        Ser or Asn
 <220>
 <221>
       MISC FEATURE
 <222>
        (4)...(4)
 <223>
        Any aliphatic amino acid
 <220>
```

<220>

```
<221>
      misc_feature
<222>
       (6)..(6)
<223>
      Xaa can be any naturally occurring amino acid
<400> 4
Xaa Xaa Xaa Val Ser Xaa
<210>
       5
<211>
       18
<212>
       PRT
<213> Artificial
<220>
<223> Modified targeting signal in the final antibody heavy chain
<220>
<221>
      MISC_FEATURE
<222>
       (3)..(3)
<223> Asn, His or Leu. Preferably Leu
<220>
<221> MISC_FEATURE
<222>
       (4)..(4)
<223> Val or Tyr, preferably Val
<220>
      MISC_FEATURE
<221>
<222>
       (5)..(5)
<223> Ser or Asn
<220>
<221> MISC_FEATURE
<222>
       (8)..(8)
<223> An aliphatic amino acid, preferably Val or Leu
<220>
<221>
       MISC FEATURE
<222>
       (9)...(9)
<223> An aliphatic amino acid, preferably Ile, Val or Leu
<220>
<221>
       MISC_FEATURE
<222> (10)..(10)
<223> Met, Val or Leu, preferably Met
<220>
<221> MISC_FEATURE
<222>
       (11)^{-}. (11)
<223> Ser or Ala
<220>
       MISC_FEATURE
<221>
<222>
       (12)...(12)
<223> Asp or Glu
<220>
<221>
       MISC_FEATURE
<222>
       (13)...(13)
       Any amino acid, preferably Gly, Val, Ala or Thr
<223>
```

```
<221> MISC_FEATURE
<222>
       (14)..(14)
<223> Asp, Glu, Gly, or Ala, preferably Asp
<220>
      MISC FEATURE
<221>
<222>
      (15)..(15)
<223> Gly or Ser, preferably Gly
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Ile, Thr, Val, Glx or Ala, preferably Ile or Thr
<220>
<221> MISC FEATURE
<222>
       (18)..(18)
<223> May or may not be present and where present is Ala or Tyr. Most
       preferably, where this amino acid present it is Ala.
<400> 5
Pro Thr Xaa Xaa Xaa Val Ser Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
Cys Xaa
<210>
       6
<211>
       6
<212> PRT
<213> Artificial
<220>
<223> Modified targeting signal in the final antibody heavy chain
<220>
<221>
       MISC_FEATURE
<222>
       (1)..(1)
<223> Asn, His or Leu
<220>
<221>
       MISC_FEATURE
<222>
       (2)..(2)
<223> Val or Tyr
 <220>
 <221> MISC_FEATURE
 <222>
       (3)..(3)
 <223> Ser or Asn
 <220>
       MISC_FEATURE
 <221>
 <222>
       (6)...(6)
 <223>
       Aliphatic amino acid
 <400> 6
 Xaa Xaa Xaa Val Ser Xaa
```

```
<210> 7
<211> 28
<212> PRT
<213> Artificial
<220>
<223> Modified targeting signal in the final antibody heavy chain
<400> 7
Ser Cys Met Val Gly His Glu Ala Leu Pro Met Asn Phe Thr Gln Lys
Thr Ile Asp Arg Leu Ser Gly Lys Pro Ala Cys Tyr
<210> 8
<211> 30
<212> PRT
<213> Artificial
<220>
<223> Modified targeting signal in the final antibody heavy chain
 <400> 8
 Ser Cys Met Val Gly His Glu Ala Leu Pro Met Asn Phe Thr Gln Lys
 Thr Ile Asp Arg Leu Ser Gly Lys Pro Ala Ala Ala Cys Tyr
             20
 <210> 9
 <211> 38
 <212> PRT
 <213> Artificial
 <223> Modified targeting signal in the final antibody heavy chain
 <400> 9
 Ser Cys Met Val Gly His Glu Ala Leu Pro Met Asn Phe Thr Gln Lys
 Thr Ile Asp Arg Leu Ser Gly Lys Pro His Ala Ser Thr Pro Glu Pro
              20
  Asp Pro Val Ala Cys Tyr
          35
  <210>
         10
  <211>
         27
  <212>
         DNA
  <213> Artificial
  <220>
```

<223> Synthetic oligonucleotide

400> catcga	10 tgg aatggacctg ggttttt	27
210> 211> 212> 213>	11 27 DNA Artificial	
<220> <223>	Synthetic oligonucleotide	
<400> ccctcta	11 agac tagtagcata ggccatc	27
<210> <211> <212> <213>	12 31 DNA Artificial	
<220> <223>	Synthetic oligonucleotide	
<400> actgta	12 Igaca attoogocao otoagootao a	31
<210> <211> <212> <213>		
<220> <223>	Synthetic oligonucleotide	
<400> tgtag	13 gctga ggtggcggaa ttgtctacag t	31
<210><211><211><212><213>	32 DNA	
<220> <223>		
<400> gagca	14 gctca acagcgtttt ccgctcagtc ag	32
<220 <223		
<4003	> 15	32

WO 2004/046190

PCT/GB2003/004983

	16 32 DNA Artificial	
<220> <223>	Synthetic oligonucleotide	
<400> ttgccca	16 atga acttcgtcca gaagaccatc ga	32
	17 32 DNA Artificial	
<220> <223>	Synthetic oligonucleotide	
<400> tcgatgo	17 gtct tetggaegaa gtteatggge aa	32
<210> <211> <212> <213>	18 33 DNA Artificial	
<220> <223>	Synthetic oligonucleotide	
<400> aaaccca	18 acca atgtcgctgt gtctgtgatc atg	33
<210> <211> <212> <213>	19 33 DNA Artificial	
<220> <223>	Synthetic oligonucleotide	
<400> catgato	19 caca gacacagcga cattggtggg ttt	33
<210> <211> <212> <213>	20 30 DNA Artificial	
<220> <223>	Synthetic oligonucleotide	
<400> ccctcta	20 agac tatttacccg acagacggtc	30
<210><211><211><212><213>	21 32 DNA Artificial	

7/19

32

<220> <223> Synthetic oligonucleotide <400> 21 gagcagctca acagcgtttt ccgctcagtc ag <210> 22 <211> 8 <212> PRT <213> Artificial <220> <223> Tailpiece of artificial C-terminus of heavy chain <400> 22 Pro Ala Ala Ala Ala Cys Tyr <210> 23 <211> 40 <212> PRT <213> Mus musculus <400> 23 Cys Met Val Gly His Glu Ala Leu Pro Met Asn Phe Thr Gln Thr Ile 5 Asp Arg Leu Ser Gly Lys Pro Thr Asn Val Ser Val Ser Val Ile Met 20 Ser Glu Gly Asp Gly Ile Cys Tyr <210> 24 <211> 23 <212> PRT <213> Mus musculus <400> 24 Cys Ser Val Leu His Glu Gly Leu His Asn His His Thr Glu Lys Ser 5 Leu Ser His Ser Pro Gly Lys 20 <210> 25 <211> 25 <212> PRT <213> ALC_MOUSE <400> 25 Ile Asp Arg Leu Ser Gly Lys Pro Thr Asn Val Ser Val Ser Val Ile Met Ser Glu Gly Asp Gly Ile Cys Tyr 20

<210> 26

<211> 25

<212> PRT

<213> Q9DCD9

<400> 26

Ile Asp Arg Leu Ser Gly Lys Pro Thr Asn Val Ser Val Ser Val Ile

Met Ser Glu Gly Asp Gly Ile Cys Tyr 20

<210> 27

<211> 25

<212> PRT

<213> Q91WP5

<400> 27

Ile Asp Arg Leu Ser Gly Lys Pro Thr Asn Val Ser Val Ser Val Ile

Met Ser Glu Gly Asp Gly Ile Cys Tyr

<210> 28 <211> 25 <212> PRT <213> Q99M22

<400> 28

Ile Asp Arg Leu Ser Gly Lys Pro Thr Asn Val Ser Val Ser Val Ile

Met Ser Glu Gly Asp Gly Ile Cys Tyr 20

<210> 29

<211> 25

<212> PRT

<213> Q91XE1

<400> 29

Ile Asp Arg Leu Ser Gly Lys Pro Thr Asn Val Ser Val Ser Val Ile

Met Ser Glu Gly Asp Gly Ile Cys Tyr

```
<210> 30
<211> 25
<212> PRT
<213> AAH29188
<400> 30
Ile Asp Arg Leu Ser Gly Lys Pro Thr Asn Val Ser Val Ser Val Ile
Met Ser Glu Gly Asp Gly Ile Cys Tyr
            20
<210>
       31
<211> 25
<212> PRT
<213> Q91WT1
<400> 31
Ile Asp Arg Leu Ser Gly Lys Pro Thr Asn Val Ser Val Ser Val Ile
                                       10
Met Ser Glu Gly Asp Gly Ile Cys Tyr
<210> 32
<211> 25
<212> PRT
<213> Q91WT3
<400> 32
Ile Asp Arg Leu Ser Gly Lys Pro Thr Asn Val Ser Val Ser Val Ile
Met Ser Glu Gly Asp Gly Ile Cys Tyr
             20
<210> 33
<211> 25
<212> PRT
<213> Q8VCV5
<400> 33
 Ile Asp Arg Leu Ser Gly Lys Pro Thr Asn Val Ser Val Ser Val Ile
                                       10
Met Ser Glu Gly Asp Gly Ile Cys Tyr
```

<210> 34 <211> 25 <212> PRT <213> Q91X92 <400> 34

Ile Asp Arg Leu Ser Gly Lys Pro Thr Asn Val Ser Val Ser Val Ile

Met Ser Glu Gly Asp Gly Ile Cys Tyr

<210> 35 <211> 25 <212> PRT

<213> AAH28249

<400> 35

Ile Asp Arg Leu Ser Gly Lys Pro Thr Asn Val Ser Val Ser Val Ile

Met Ser Glu Gly Asp Gly Ile Cys Tyr

<210> 36

<211> 25 <212> PRT <213> Q8VEA0

<400> 36

Ile Asp Arg Leu Ser Gly Lys Pro Thr Asn Val Ser Val Ser Val Ile

Met Ser Glu Gly Asp Gly Ile Cys Tyr

<210> 37

<211> 25 <212> PRT

<213> Q99LA6

<400> 37

Ile Asp Arg Leu Ser Gly Lys Pro Thr Asn Val Ser Val Ser Val Ile

Met Ser Glu Gly Asp Gly Ile Cys Tyr

<210> 38

<211> 25

<212> PRT

<213> Q91Z07

<400>

Ile Asp Arg Leu Ser Gly Lys Pro Thr Asn Val Ser Val Ser Val Ile 10

Met Ser Glu Gly Asp Gly Ile Cys Tyr 20

<210> 39

<211> 25 <212> PRT

<213> Q99KA4

<400> 39

Ile Asp Arg Leu Ser Gly Lys Pro Thr Asn Val Ser Val Ser Val Ile

Met Ser Glu Gly Asp Gly Ile Cys Tyr 20

<210> 40

<211> 25

<212> PRT

<213> Q91WR1

<400> 40

Ile Asp Arg Leu Ser Gly Lys Pro Thr Asn Val Ser Val Ser Val Ile

Met Ser Glu Gly Asp Gly Ile Cys Tyr 20

<210> 41

<211> 25

<212> PRT

<213> AAH31703

<400> 41

Ile Asp Arg Leu Ser Gly Lys Pro Thr Asn Val Ser Val Ser Val Ile 10

Met Ser Glu Gly Asp Gly Ile Cys Tyr 20

<210> 42

<211> 25

<212> PRT

<213> Q8VCX4

<400> 42

Ile Asp Arg Leu Ser Gly Lys Pro Thr Asn Val Ser Val Ser Val Ile 10

Met Ser Glu Gly Asp Gly Ile Cys Tyr 20

<210> 43
<211> 25
<212> PRT
<213> ALC2_HUMAN
<400> 43

Ile Asp Arg Leu Ala Gly Lys Pro Thr His Val Asn Val Ser Val Val
1 5 10 15

Met Ala Glu Val Asp Gly Thr Cys Tyr 20 25

<210> 44 <211> 25 <212> PRT <213> ALC1_GORGO <400> 44

Ile Asp Arg Leu Ala Gly Lys Pro Thr His Val Asn Val Ser Val Val 1 5 10 15

Met Ala Glu Val Asp Gly Thr Cys Tyr 20 25

<210> 45 <211> 25 <212> PRT <213> ALC1_HUMAN <400> 45

Ile Asp Arg Leu Ala Gly Lys Pro Thr His Val Asn Val Ser Val Val 1 5 10 15

Met Ala Glu Val Asp Gly Thr Cys Tyr 20 25

<210> 46 <211> 25 <212> PRT <213> Q9UP60 <400> 46

Ile Asp Arg Leu Ala Gly Lys Pro Thr His Val Asn Val Ser Val Val 1 5 10 15

Met Ala Glu Val Asp Gly Thr Cys Tyr 20 25

<210> 47 <211> 25 <212> PRT <213> Q9NPP6

PCT/GB2003/004983

<400> 47

Ile Asp Arg Leu Ala Gly Lys Pro Thr His Val Asn Val Ser Val Val 1 5 10 15

Met Ala Glu Val Asp Gly Thr Cys Tyr
20 25

<210> 48

<211> 25

<212> PRT

<213> BAC11114

<400> 48

Ile Asp Arg Leu Ala Gly Lys Pro Thr His Val Asn Val Ser Val Val 1 5 10 15

Met Ala Glu Val Asp Gly Thr Cys Tyr
20 25

<210> 49

<211> 25

<212> PRT

<213> Q96K68

<400> 49

Ile Asp Arg Leu Ala Gly Lys Pro Thr His Val Asn Val Ser Val Val 1 5 10 15

Met Ala Glu Val Asp Gly Thr Cys Tyr
20 25

<210> 50

<211> 25

<212> PRT

<213> Q96KX8

<400> 50

Ile Asp Arg Leu Ala Gly Lys Pro Thr His Val Asn Val Ser Val Val 1 5 10 15

Met Ala Glu Val Asp Gly Thr Cys Tyr 20 25

<210> 51

<211> 25

<212> PRT

<213> Q96DK0

<400> 51

Ile Asp Arg Leu Ala Gly Lys Pro Thr His Val Asn Val Ser Val Val 1 5 10 15

Met Ala Glu Val Asp Gly Thr Cys Tyr

<210> 52

<211> 25

<212> PRT

<213> Q8WY24

<400> 52

Ile Asp Arg Leu Ala Gly Lys Pro Thr His Val Asn Val Ser Val Val

Met Ala Glu Val Asp Gly Thr Cys Tyr 20

<210> 53 <211> 25 <212> PRT

<213> AAH32249

<400> 53

Ile Asp Arg Leu Ala Gly Lys Pro Thr His Val Asn Val Ser Val Val 10

Met Ala Glu Val Asp Gly Thr Cys Tyr

<210> 54 <211> 25 <212> PRT <213> Q9BRV0

<400> 54

Ile Asp Arg Leu Ala Gly Lys Pro Thr His Val Asn Val Ser Val Val

Met Ala Glu Val Asp Gly Thr Cys Tyr -20

<210> 55

<211> 25 <212> PRT

<213> ALC_RABIT

<400> 55

Ile Asp Arg Leu Ala Gly Lys Pro Thr His Val Asn Val Ser Val Val

Val Ala Asp Val Glu Ala Val Cys Tyr 20

```
PCT/GB2003/004983
16/19
```

<210> 56 <211> 25 <212> PRT <213> MUS MESAU

<400> 56

Val Asp Arg Ser Thr Gly Lys Pro Thr Leu Tyr Asn Val Ser Leu Ile 10

Met Ser Asp Ala Gly Gly Thr Cys Tyr

<210> 57 25 <211>

<212> PRT

<213> MUC_MOUSE

<400> 57

Val Asp Lys Ser Thr Gly Lys Pro Thr Leu Tyr Asn Val Ser Leu Ile

Met Ser Asp Thr Gly Gly Thr Cys Tyr

<210> 58

<211> 25 <212> PRT <213> Q9BSZ1

<400> 58

Val Asp Lys Ser Thr Gly Lys Pro Thr Leu Tyr Asn Val Ser Leu Val

Met Ser Asp Thr Ala Gly Thr Cys Tyr 20

<210> 59

<211> 25

<212> PRT <213> MUCB_HUMAN

<400> 59

Val Asp Lys Ser Thr Gly Lys Pro Thr Leu Tyr Asn Val Ser Leu Val

Met Ser Asp Thr Ala Gly Thr Cys Tyr

<210> 60

<211> 25

<212> PRT

<213> MUC_HUMAN

<400> 60

Val Asp Lys Ser Thr Gly Lys Pro Thr Leu Tyr Asn Val Ser Leu Val 1 5 10 15

Met Ser Asp Thr Ala Gly Thr Cys Tyr 20 25

<210> 61

<211> 25

<212> PRT

<213> Q9BQB8

<400> 61

Val Asp Lys Ser Thr Gly Lys Pro Thr Leu Tyr Asn Val Ser Leu Val

Met Ser Asp Thr Ala Gly Thr Cys Tyr
20 25

<210> 62

<211> 25

<212> PRT

<213> Q9BU10

<400> 62

Val Asp Lys Ser Thr Gly Lys Pro Thr Leu Tyr Asn Val Ser Leu Val 1 5 10 15

Met Ser Asp Thr Ala Gly Thr Cys Tyr 20 25

<210> 63

<211> 25

<212> PRT

<213> Q96BB9

<400> 63

Val Asp Lys Ser Thr Gly Lys Pro Thr Leu Tyr Asn Val Ser Leu Val 1 5 10 15

Met Ser Asp Thr Ala Gly Thr Cys Tyr
20 25

<210> 64

<211> 25

<212> PRT

<213> MUC_CANFA

<400> 64

Val Asp Lys Ser Thr Gly Lys Pro Thr Leu Tyr Asn Val Ser Leu Val 1 5 10 15 18/19

```
Leu Ser Asp Thr Ala Gly Thr Glx Tyr
            20
```

<210> 65

<211> 25

<212> PRT

<213> MUC SUNMU

<400> 65

Val Asp Lys Thr Ser Gly Lys Pro Thr Leu Tyr Asn Val Ser Leu Val

Leu Ser Asp Thr Ala Ser Thr Cys Tyr

<210> 66

<211> 25

<211> 25
<212> PRT

<213> MUC_RABIT

<400> 66

Val Asp Lys Ser Thr Gly Lys Pro Thr Leu Tyr Asn Val Ser Leu Ile 10

Met Ser Asp Thr Ala Ser Thr Cys Tyr 20 25

<210> 67

<211> 25 <212> PRT

<213> MUC_CHICK

<400> 67

Val Asp Arg Ala Ser Gly Lys Ala Ser Ala Val Asn Val Ser Leu Val 10

Leu Ala Asp Ser Ala Ala Ala Cys Tyr

<210> 68

<211> 22

<212> PRT

<213> Q8YOT9

<400> 68

Arg Ile Gly Gly Pro Pro Thr Gly Ile Thr Ser Asp Val Tyr Leu Ser 10

Val Tyr Glu Gly Val Cys 20

<210> 69
<211> 32
<212> PRT
<213> Artificial

<220>
<223> Modified targeting signal in the final antibody heavy chain
<400> 69
Ser Cys Met Val Gly His Glu Ala Leu Pro Met Asn Phe Thr Gln Lys
1 15

Thr Ile Asp Arg Leu Ser Gly Lys Pro Ala Ala Ala Ala Ala Cys Tyr 20 25 30